amecath ureteral balloon dilator
أميكو ميديكال للصناعات الطبية -
amecath. ureteral access sheath.
أميكو ميديكال للصناعات الطبية -
implant template, single use, for the sonata ti 100 reference: 03875
الامين للتجهيزات الطبية والمعملية (أميكو) -
hyabak 0.15%
الامين للتجهيزات الطبية والمعملية (أميكو) -
nex-acri aa 1p hydrophobic acrylic single piece posterior chamber intraocular lens, model number: ns-60yg.
الامين للتجهيزات الطبية والمعملية (أميكو) -
saridon tab 250 mg, 150 mg, 50 mg
شركة مستودع الأدوية الأردني - the jordan drugstore co - paracetamol 250 mg, propyphenazone 150 mg, caffeine 50 mg - 250 mg, 150 mg, 50 mg
saridon tab 250 mg, 150 mg, 50 mg
مستودع خوري - khoury drug store - paracetamol 250 mg, propyphenazone 150 mg, caffeine 50 mg - 250 mg, 150 mg, 50 mg
renvela 800 mg tablets
sanofi israel ltd - sevelamer carbonate anhydrous - film coated tablets - sevelamer carbonate anhydrous 800 mg - sevelamer - sevelamer - for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus ≥ 1.78 mmol/l.should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.
scemblix 20 mg
novartis israel ltd - asciminib as hydrochloride - film coated tablets - asciminib as hydrochloride 20 mg - asciminib - scemblix is indicated for the treatment of adult patients with:• philadelphia chromosome-positive chronic myeloid leukemia (ph+ cml) in chronic phase (cp), previously treated with two or more tyrosine kinase inhibitors (tkis).• ph+ cml in cp with the t315i mutation
scemblix 40 mg
novartis israel ltd - asciminib as hydrochloride - film coated tablets - asciminib as hydrochloride 40 mg - asciminib - scemblix is indicated for the treatment of adult patients with:• philadelphia chromosome-positive chronic myeloid leukemia (ph+ cml) in chronic phase (cp), previously treated with two or more tyrosine kinase inhibitors (tkis).• ph+ cml in cp with the t315i mutation